Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
about
Novel Therapies for Eosinophilic DisordersEosinophilia in Hematologic DisordersHypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.Eosinophilic myeloproliferative disordersNovel targeted therapies for eosinophil-associated diseases and allergyA review of vitamin B12 in dermatology.Advances in diagnosis and treatment of eosinophiliaTherapeutic approaches to patients with hypereosinophilic syndromes.How I treat hypereosinophilic syndromes.The Spectrum of FIP1L1-PDGFRA-Associated Chronic Eosinophilic Leukemia: New Insights Based on a Survey of 44 CasesLong-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.Eosinophilic gastrointestinal disorders (EGID) with peripheral eosinophilia: a retrospective review at Mayo Clinic.World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.Clinical overview of cutaneous features in hypereosinophilic syndrome.Clinical management of the hypereosinophilic syndromes.World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.Biological Modulators in Eosinophilic Diseases.Clinical features predict responsiveness to imatinib in platelet-derived growth factor receptor-alpha-negative hypereosinophilic syndrome.Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activitiesHypereosinophilic syndrome variants: diagnostic and therapeutic considerations.Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia.Cessation of imatinib mesylate may lead to sustained hematologic and molecular remission in FIP1L1-PDGFRA-mutated hypereosinophilic syndrome.Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients.Clinical and Biological Markers in Hypereosinophilic Syndromes.Imatinib for the treatment of hypereosinophilic syndromes.Imatinib Treatment in PDGFRA-Negative Childhood Hypereosinophilic Syndrome.Imatinib discontinuation for hypereosinophilic syndrome harboring the FIP1L1-PDGFRA transcript.Diagnosis and Novel Approaches to the Treatment of Hypereosinophilic Syndromes.Congenital and childhood myeloproliferative disorders with eosinophilia responsive to imatinib.Long-term therapy-free remission in a patient with platelet-derived growth factor receptor beta-rearranged myeloproliferative neoplasm.
P2860
Q26799600-4E48D043-E0B5-4D5A-B7EF-3F3E376A1BC2Q26799611-3F6DACFE-4035-4F52-87B4-1156E45F75A4Q33620407-4E7AF252-438F-40E3-AABC-CE9F9FE02F7EQ33881283-EBDCBF5E-2FE0-4C38-BB44-2CA355B018BCQ34444620-5A3F95FC-C3BA-42A7-A895-361144FAB119Q34456556-C74CC370-31B0-4628-B91E-77FF4767321FQ34895664-053E1A62-F357-4EFD-AFCC-F25AAE5A94DDQ35857340-62EA4E33-79F7-4F3C-AF3C-25119AF2F88BQ36000858-91A65618-B378-481E-B89F-889BA05618EEQ36008991-5156276E-A977-44F5-891C-A7737924EF4FQ37362888-F850286F-46CD-48D0-82CD-9AD6E6B7FDAAQ37886794-6FBBA913-2931-4918-97E6-3828BCEC2FFAQ37901437-1A89D896-7824-4341-9796-863E94B51235Q37987470-42821519-E667-4089-A118-A32DD7215A87Q38025157-F12387AD-A713-47A1-B8DD-1BDD6D6A1FF4Q38038509-A28CBF86-2CF6-4F69-AD10-B8C5530B7BF3Q38131481-E2E9423D-2641-4E0E-B06B-3EE1D4B99874Q38191834-8EB45B13-59B1-4E62-AD98-93BBCCED3099Q38240474-B610548A-44C7-42EA-A009-BAA3820BC7F7Q40822125-31F50CE5-06FF-4929-AF8F-302D704086CAQ41786014-FA96DC8F-8C75-4FD7-8530-1F365C3B9B19Q42547373-43B803DF-366E-4E27-96FF-DA9890E19F7FQ42704283-7B215E4B-31BD-47A2-905A-FD5DDD52745DQ43470981-3A4F08C6-E55E-4664-9E9C-E1063A2DA452Q44909035-ED23FAD1-1716-4E07-BF1A-D2D51821DF16Q46026437-5994174C-158B-49D5-898C-5ABC5A382AE6Q46727966-591472A3-8615-40D6-B8C2-EBE257186A42Q49248245-06B7C9F0-7155-48B6-B627-2F95FF2DB89FQ50177622-C2A5B2A7-669B-4B77-A8C2-6DF93903F15EQ50996871-3BDD530D-155E-40F6-84DC-63BD5723D029Q52912578-12147FD3-C5DD-4F0A-9005-F27419A02759Q54114931-EE220C84-CE24-4D4C-AE3C-FBE70FF246DDQ54518482-03E20E5F-3C60-4331-A3E6-38AA0A2CBD40Q55022456-28E73A25-3918-4CF5-A5AF-0C6563C68983
P2860
Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Relapse following discontinuat ...... plications for optimal dosing.
@ast
Relapse following discontinuat ...... plications for optimal dosing.
@en
type
label
Relapse following discontinuat ...... plications for optimal dosing.
@ast
Relapse following discontinuat ...... plications for optimal dosing.
@en
prefLabel
Relapse following discontinuat ...... plications for optimal dosing.
@ast
Relapse following discontinuat ...... plications for optimal dosing.
@en
P2093
P2860
P50
P1433
P1476
Relapse following discontinuat ...... plications for optimal dosing.
@en
P2093
Cheryl Talar-Williams
Irina Maric
Jamie Robyn
Laura Schmid
Marilyn Hartsell
Melissa A Law
Pierre Noel
Steven Lemery
Weiming Fu
P2860
P304
P356
10.1182/BLOOD-2007-07-100164
P407
P577
2007-08-20T00:00:00Z